CeriBell, Inc logo

CeriBell, Inc(CBLL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 66 days
PROFIT SINCE LAST BUY
+12.43% ▲
LAST CLOSE
$26.14
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CBLL

11/13/2026: CBLL (2-star) has a low Upturn Star Rating. Not recommended to BUY.

CeriBell, Inc. is a commercial-stage medical technology stock that provides a point-of-care EEG platform designed to rapidly assess serious neurological conditions in acute care settings. The company's primary business strengths include high gross profit margins, rapid hospital adoption exceeding 600 accounts, and a high-margin recurring revenue model driven by disposable headbands and AI software subscriptions. Its core investment growth story centers on expanding hospital penetration and introducing new FDA-cleared indications such as delirium monitoring. However, investors must weigh execution risks, ongoing net operating losses, and valuation sensitivities typical of emerging medtech growth firms. The stock best suits growth-oriented investors willing to tolerate volatility while monitoring ongoing account acquisition rates and progress toward profitability.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitCeriBell exhibits rapid top-line revenue growth and expanding hospital adoption in the acute care market.
Momentum investorStrong fit while signal remains positiveThe stock attracts attention during periods of strong quarterly revenue growth reports and positive clinical catalysts.
Value investorWeak fitThe company currently operates at a net loss as it prioritizes commercial scaling over near-term profitability.
Dividend investorWeak fitCeriBell does not pay dividends, choosing instead to reinvest capital into business expansion.
Low-risk investorWeak fitAs a commercial-stage medtech stock experiencing high volatility and operating losses, it carries notable execution risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighEmerging growth medical technology stocks frequently experience sharp price movements based on earnings results and market sentiment.
Valuation riskMedium / highValuation relies heavily on sustaining high future revenue growth rates and achieving long-term profitability targets.
Competition risk (traditional and AI neurodiagnostic alternatives)MediumThe company faces established medical device players seeking to introduce competing point-of-care monitoring features.
Business qualityMedium / highHigh gross margins and recurring disposable sales indicate solid business fundamentals despite ongoing net operating losses.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskMedium / highSuccess depends on expanding hospital account penetration and successfully commercializing new indications like delirium monitoring.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.02B USD
Price to earnings Ratio -
1Y Target Price 31.57
Price to earnings Ratio -
1Y Target Price 31.57
Volume (30-day avg) 549.3K shares
Beta 0.86
52 Weeks Range 12.65 - 28.89
Updated Date 11/15/2026
52 Weeks Range 12.65 - 28.89
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.95

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -15.95%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CBLL receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CBLL has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, strong revenue growth (+36.1%) is partially offset by negative earnings growth (-32.0%), weak cash generation (FCF margin -46.7%), weak profitability (net margin -60.0%).

Financial Health Rating

★★★★★
CBLL's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 85.6%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is CBLL's strongest growth driver at +36.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-32.0%, negative) and free-cash-flow growth (-14.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.7% and approximately 69.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 11.86% supports management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 14.66%
TPG GP A, LLC 9.69%
Red Tree Management, LLC 5.68%
BlackRock Inc 4.99%
Vanguard Capital Management, LLC 2.91%

Unit Economics (Per $1K Revenue)

★★★★★
CBLL generates approximately $879 of gross profit, $-656 of operating income, and $-467 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CBLL has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
EEG Recorders & Disposable HeadbandsPoint-of-care hardware units and single-use, flexible headbands sold to hospitals on a recurring basis.This is the primary revenue driver, representing roughly three-quarters of total sales as hospitals continuously reorder consumables.
EEG Portal & Clarity SubscriptionsCloud-based software licenses, AI seizure-triage analytics, and remote specialist access portals.Provides high-margin recurring software income that scales alongside hospital network adoption.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 919.72M
Price to Sales(TTM) 9.34
Enterprise Value 919.72M
Price to Sales(TTM) 9.34
Enterprise Value to Revenue 8.46
Enterprise Value to EBITDA -
Shares Outstanding 38.84M
Shares Floating 27.01M
Shares Outstanding 38.84M
Shares Floating 27.01M
Percent Insiders 11.86
Percent Institutions 93.68

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.